8-K
filed January 25, 2024, 6:59 PM ET
ticker LNAI
CIK 0001527728
M&A
confidence high
sentiment positive
materiality 0.70
Renovaro shareholders approve all proposals to advance GEDi Cube acquisition
Lunai Bioworks Inc.
- Shareholders approved share issuance for GEDi Cube Intl Ltd acquisition under Stock Purchase Agreement.
- Authorized capital stock increased from 110M to 360M shares; common stock from 100M to 350M.
- Approved decrease of exercise price for outstanding stock options to closing price on deal date.
- Approved 5M share increase for awards under 2023 Equity Incentive Plan.
- All five proposals passed with strong support; over 46% voting power represented at meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lunai Bioworks Inc. shareholders approved Approval of issuance of shares of Common Stock pursuant to the Stock Purchase Agreement at the 2024-01-25 meeting.
- Proposal
- merger approval
- Outcome
- passed
- Meeting
- 2024-01-25
Exact text from the filing
Proposal No. 1 : Approval, for purposes of Listing Rule 5635 of The Nasdaq Stock Market LLC (“Nasdasq”), of the issuance of shares of Common Stock , pursuant to the Stock Purchase Agreement
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lunai Bioworks Inc. shareholders approved Amendment to increase authorized shares of capital stock at the 2024-01-25 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2024-01-25
Exact text from the filing
Proposal No. 2 : Approval of an amendment to Renovaro’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of capital stock of Renovaro from one hundred ten million (110,000,000) to three hundred sixty million (360,000,000)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lunai Bioworks Inc. shareholders approved Amendment to 2023 Plan to increase shares available for awards by 5,000,000 at the 2024-01-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2024-01-25
Exact text from the filing
Proposal No. 4 : Approval of an amendment to the 2023 Plan to increase the number of shares of Common Stock available for awards under the 2023 Plan by five million (5,000,000) shares . The stockholders approved this proposal as follows: Votes For 32,145,204 Votes Against 45,717 Abstentions 2,601 Broker Non-Votes 1,394,478
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lunai Bioworks Inc. shareholders approved Approval to adjourn meeting if necessary for proxy solicitation at the 2024-01-25 meeting.
- Outcome
- passed
- Meeting
- 2024-01-25
Exact text from the filing
Proposal No. 5 : Approval to adjourn the Meeting, if necessary, for the purpose of soliciting additional proxies to approve any one or more of the foregoing proposals to be considered at the Meeting
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lunai Bioworks Inc. shareholders approved Decrease in exercise price of outstanding stock options under the 2019 and 2023 Equity Incentive Plans at the 2024-01-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2024-01-25
Exact text from the filing
Proposal No. 3 : Approval of a decrease in the exercise price of the outstanding stock options held by Renovaro’s employees and consultants granted pursuant to the Enochian BioSciences Inc. 2019 Equity Incentive Plan
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.